▲ +190.09% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Applied Therapeutics in the last 3 months. The average price target is $63.50, with a high forecast of $85.00 and a low forecast of $44.00. The average price target represents a 190.09% upside from the last price of $21.89.
The current consensus among 5 contributing investment analysts is to buy stock in Applied Therapeutics.
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that is in phase I/II for the treatment of galactosemia; AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy; and AT-003 that is in phase I clinical trial for the treatment diabetic retinopathy. The company's preclinical stage products include AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.